{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-23-000079","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.466485+00:00","generated_at":"2026-06-12T04:47:58.229022+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Maravai Q2 revenue $68.9M, down 72%; net loss $11.9M; CEO transition to Trey Martin","bullets":["Revenue $68.9M, down 71.6% YoY; net loss $(11.9)M vs net income $156.7M prior year.","Nucleic Acid Production revenue $53.3M (-76.4%), including $11.6M CleanCap; Biologics Safety Testing $15.6M (-10.5%).","Appointed Trey Martin as CEO effective July 27, 2023; Carl Hull remains Executive Chair.","Took occupancy of new 32,000-sq-ft cGMP mRNA facility in San Diego; expanded enzyme R&D in Florida.","Updated 2023 financial guidance conservatively; no specific numbers provided in filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-23-000079","json":"https://secwatch.observer/filing/0001823239-23-000079.json","markdown":"https://secwatch.observer/filing/0001823239-23-000079.md","text":"https://secwatch.observer/filing/0001823239-23-000079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000079/0001823239-23-000079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000079/mrvi-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:47:58.229022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1dc3df7d355d9a634e35ccac14149e936c500435","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. updated its the full year 2023 guidance (lowered).","evidence_excerpt":"we are taking a more conservative view of our financial guidance for the full year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000079/0001823239-23-000079-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2023"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"77e55b32a1219239e19a6309d48ac4ac868e1950","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported the six months ended June 30, 2023 results: revenue $147.9 million, net income Net loss ... $(13.3) million. Guidance reaffirmed.","evidence_excerpt":"Revenue for the six months ended June 30, 2023 was $147.9 million, representing a 70% decrease over the same period in the prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000079/0001823239-23-000079-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Revenue","value":"$147.9 million"},{"label":"Net income","value":"Net loss ... $(13.3) million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7a778757e951a34f9ca184f56b193e63207d1ff1","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported the second quarter ended June 30, 2023 results: revenue $68.9 million, net income Net loss of $(11.9) million. Guidance reaffirmed.","evidence_excerpt":"innovators, today reported financial results for the second quarter ended June 30, 2023, together with other business updates. Recent highlights include: • Quarterly revenue of $68.9 million, Net loss of $(11.9) million, and Adjusted EBITDA margin of 13.2%; • Completed planned leadership transition with the appointment of Trey Martin as CEO effective July 27, 2023,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000079/0001823239-23-000079-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$68.9 million"},{"label":"Net income","value":"Net loss of $(11.9) million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}